Elsevier

Advanced Drug Delivery Reviews

Volume 59, Issue 11, 30 September 2007, Pages 1162-1176
Advanced Drug Delivery Reviews

The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems

https://doi.org/10.1016/j.addr.2007.04.019Get rights and content

Abstract

Mammalian models are frequently used for preclinical evaluation of new drug delivery systems (DDS). However, valid mammalian models are expensive, time-consuming, and not easy to set up and evaluate. Furthermore, they are often linked to administrative burden with respect to ethical and legal aspects. The present review outlines the possibilities and limitations of using the hen's embryo, and specifically its chorioallantoic membrane (CAM), as an alternative to mammalian models for the evaluation of DDS. Features of the CAM, the anatomy of the embryo, and the blood were investigated to assess properties of the drug carriers such as toxicity and biocompatibility, as well as the activity, toxicity, biodistribution and pharmacokinetics of the drug. The simplicity, rapidity, and low cost of the different assays that can be performed with chick embryos strengthen the interest of routinely using this model in pharmaceutical technology research. It is concluded that there is a big potential for using chick embryos in screening procedures of formulation candidates, thus establishing an intermediate step between in vitro cellular tests and preclinical mammalian models.

Introduction

Nowadays, the pharmaceutical field faces an ever growing demand for making innovative formulations that are able to “intelligently” deliver modern active compounds. The development of high-throughput strategies for the discovery, synthesis, and screening of drugs, as well as the advances in genomics and proteomics, have resulted in a huge amount of new drug candidates for which formulations need to be designed. In this context, drugs, such as peptides, proteins, monoclonal antibodies, and nucleic acids, are particularly difficult to formulate. Progress in both polymer and biomaterial sciences offers the possibility of using new excipients for developing improved drug carriers. Ideally, delivery systems should have adequate drug loading, remain stable during storage and biodistribution, accumulate selectively at the target site, be able to release the drug in a controlled manner, be biodegradable, and perfectly biocompatible. To achieve these requirements, formulations have become increasingly complex. Although the use of high-throughput systems may accelerate both the formulation phases and the in vitro evaluation of drug delivery systems (DDS) [1], preclinical assays using mammalian models are still time-consuming. Furthermore, limits from ethical and legal points of view for working with those models are already very restrictive and are increasing steadily [2].

The chick embryo is a well-known animal model, which has been extensively studied from Aristotle's time—who opened hen's eggs daily to examine progressive stages of embryogenesis [3]—until the modern molecular era. The increasing interest in the chick embryo as a model in biological and pharmaceutical research is related to its simplicity and low cost compared with mammalian models. Current laws regulating animal experimentation in the USA, the European Union, and Switzerland allow experimentation with chick embryos without authorization from animal experimentation committees, on the grounds that experiments begin and end before hatching. Nevertheless, experimentation with chick embryos must be refined to reduce the number of embryos used through adequate experimental design.

The present review outlines the potential use of the chick embryo, and specifically its chorioallantoic membrane (CAM), as an alternative to mammalian models for the evaluation of DDS. The CAM of the developing chick embryo is an extraembryonic membrane mediating gas and nutriment exchanges until hatching. Since the CAM has a very dense capillary network, it is commonly used to study in vivo both new vessel formation (angiogenesis) and its inhibition in response to different factors. In the literature, the use of CAM in research is referred to as the CAM assay or as the CAM model.

Although chick embryos are not widely used for the evaluation of new drug carriers, the United States Food and Drug Administration (FDA) has approved products preclinically evaluated with chick embryos. Indeed, a FDA guidance for industry, published in June 2006, regarding the development of products for the treatment of chronic cutaneous ulcer and burn wounds, considered the CAM model as an alternative for preclinical testing. Various papers summarized the different applications of the CAM model in areas of interest for the pharmaceutical community, such as angiogenesis and antiangiogenesis [4], [5], [6], wound healing [7], tissue engineering [8], biomaterials and implants [9], [10], [11], and biosensors [12].

The scope of the present review has been restricted to studies regarding the evaluation of DDS with the CAM model. The biological and physiological characteristics of the CAM are presented, as well as the protocols for embryo cultivation and administration of formulations. The use of chick embryos for the evaluation of drug activity, toxicity, biocompatibility, pharmacokinetics, and biodistribution are also summarized, concluding with an outline on the advantages and limitations, as well as some perspectives in the use of this model in pharmaceutical research.

Section snippets

Chick embryo and its chorioallantoic membrane

Chick embryo development lasts 21 days before hatching. Hamburger and Hamilton classified the embryo development depending on a series of stages designed based on the external characteristics of the embryo [13]. The 21-day incubation period corresponds to 46 stages, known as the HH stages, which are not uniformly distributed over the time of development. However, in most studies on DDS, a different classification is followed: the first day of incubation is considered as the first day of

Chick embryos for drug delivery systems evaluation

Pharmaceutical technology scientists make huge efforts to produce new delivery systems capable of regulating the rate of drug delivery, sustaining the duration of the therapeutic action, and/or targeting the delivery of drugs. During the development of DDS, chick embryos can be used to evaluate the activity or toxicity of a drug on both the CAM and CAM-grafted tumors, as well as on the development of the body of the embryo. Toxicity of drugs or carriers on chick embryos can be evaluated in

Advantages and limitations of chick embryos for evaluating drug delivery systems

The interest in using chick embryos for the early evaluation of DDS has been outlined in this overview. However, the chick embryo is still a model and presents some advantages and limitations that are summarized in Table 4. The use of the chick embryo, as a whole living organism, overcomes some limitations encountered when working with simple in vitro systems frequently used in the pharmaceutical field. Although, in vitro drug release in simulated biological media and in vitro cellular models

Conclusions and perspectives

Although the chick embryo and its chorioallantoic membrane have been extensively used to study both angiogenesis and antiangiogenesis processes, its potential use has not been fully exploited in pharmaceutics and biopharmaceutics. Most of the DDS evaluated with the CAM model incorporated drugs modifying the vasculature, such as pro-, antiangiogenic molecules and PS. The strategy frequently used is to optimize the formulations in terms of excipients, drug loading, and other properties by in vitro

References (97)

  • D.M. Bagley et al.

    Development of a 10-day chorioallantoic membrane vascular assay as an alternative to the Draize rabbit eye irritation test

    Food Chem. Toxicol.

    (1994)
  • R.G. Alany et al.

    W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention

    J. Control. Release

    (2006)
  • L.M. Kirchner et al.

    Quantitation of angiogenesis in the chick chorioallantoic membrane model using fractal analysis

    Microvasc. Res.

    (1996)
  • J.M. Kanczler et al.

    Supercritical carbon dioxide generated vascular endothelial growth factor encapsulated poly(D,L-lactic acid) scaffolds induce angiogenesis in vitro

    Biochem. Biophys. Res. Commun.

    (2007)
  • M.D. Kofron et al.

    Bone tissue engineering by gene delivery

    Adv. Drug Deliv. Rev.

    (2006)
  • H.M. Burt et al.

    Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (DL-lactic acid)

    Cancer Lett.

    (1995)
  • S.K. Dordunoo et al.

    Release of taxol from poly(ɛ-caprolactone) pastes: effect of water-soluble additives

    J. Control. Release

    (1997)
  • M.S. Tartis et al.

    Therapeutic effects of paclitaxel-containing ultrasound contrast agents

    Ultrasound Med. Biol.

    (2006)
  • A. Knoll et al.

    A comparison of two controlled-release delivery systems for the delivery of amiloride to control angiogenesis

    Microvasc. Res.

    (1999)
  • P.C. Rodrigues et al.

    Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution

    Bioorg. Med. Chem.

    (1999)
  • A.P. Castano et al.

    Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization

    Photodiagn. Photodyn. Ther.

    (2004)
  • R. Klein et al.

    Prevalence of age-related maculopathy. The beaver dam eye study

    Ophthalmology

    (1992)
  • C.L. Saw et al.

    Enhanced photodynamic activity of hypericin by penetration enhancer N-methyl pyrrolidone formulations in the chick chorioallantoic membrane model

    Cancer Lett.

    (2006)
  • H. Toledano et al.

    Photodynamic damage by liposome-bound porphycenes: comparison between in vitro and in vivo models

    J. Photochem. Photobiol., B Biol.

    (1998)
  • K. Kunzi-Rapp et al.

    Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model

    J. Urol.

    (2001)
  • T. Syrovets et al.

    Inhibition of IκB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo

    J. Biol. Chem.

    (2005)
  • W.W. Chin et al.

    Chlorin e6-polyvinylpyrrolidone as a fluorescent marker for fluorescence diagnosis of human bladder cancer implanted on the chick chorioallantoic membrane model

    Cancer Lett.

    (2007)
  • C.L. Saw et al.

    Superiority of N-methyl pyrrolidone over albumin with hypericin for fluorescence diagnosis of human bladder cancer cells implanted in the chick chorioallantoic membrane model

    J. Photochem. Photobiol., B Biol.

    (2007)
  • A.H. Piersma

    Validation of alternative methods for developmental toxicity testing

    Toxicol. Lett.

    (2004)
  • M.J. Packard

    Use of slow-release pellets to administer calcitriol to avian embryos: effects on plasma calcium, magnesium, and phosphorus

    Gen. Comp. Endocrinol.

    (1992)
  • M.J. Packard

    Variation during development in the response of chicken embryos to calcitriol administered via slow-release pellets

    Gen. Comp. Endocrinol.

    (1992)
  • B. Büchele et al.

    High-performance liquid chromatographic determination of acetyl-11-keto-α-boswellic acid, a novel pentacyclic triterpenoid, in plasma using a fluorinated stationary phase and photodiode array detection: Application in pharmacokinetic studies

    J. Chromatogr., B, Biomed. Sci. Appl.

    (2005)
  • D. Meadows

    Recent developments with biosensing technology and applications in the pharmaceutical industry

    Adv. Drug Deliv. Rev.

    (1996)
  • U. Klueh et al.

    Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization

    Biomaterials

    (2005)
  • C.D. Stern

    The chick: a great model system becomes even greater

    Dev. Cell

    (2005)
  • C.B. Daniels et al.

    The comparative biology of pulmonary surfactant: past, present and future

    Comp. Biochem. Physiol., Part A Mol. Integr. Physiol.

    (2001)
  • H. Spielmann et al.

    IRAG working group 2: CAM-based assays

    Food Chem. Toxicol.

    (1997)
  • M.J. Hammer-Wilson et al.

    Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for topically applied photosensitizers

    J. Photochem. Photobiol., B Biol.

    (1999)
  • Nuffield Council on Bioethics

    The context of animal research: past and present

  • Aristotle
    (1970)
  • D. Ribatti et al.

    The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis

    Curr. Pharm. Biotechnol.

    (2000)
  • D. Ribatti et al.

    Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo

    Anat. Rec.

    (2001)
  • M. Richardson et al.

    Observations on the use of the avian chorioallantoic membrane (CAM) model in investigations into angiogenesis

    Curr. Drug Targets Cardiovasc. Haematol. Disord.

    (2003)
  • J. Borges et al.

    Chorioallantoic membrane angiogenesis model for tissue engineering: a new twist on a classic model

    Tissue Eng.

    (2003)
  • G. Zwadlo-Klarwasser et al.

    The chorioallantoic membrane of the chick embryo as a simple model for the study of the angiogenic and inflammatory response to biomaterials

    J. Mater. Sci., Mater. Med.

    (2001)
  • T.I. Valdes et al.

    The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials

    J. Biomed. Mater. Res.

    (2002)
  • U. Klueh et al.

    Ex ova chick chorioallantoic membrane as a novel model for evaluation of tissue responses to biomaterials and implants

    J. Biomed. Mater. Res.

    (2003)
  • T.I. Valdes et al.

    Ex ova chick chorioallantoic membrane as a novel in vivo model for testing biosensors

    J. Biomed. Mater. Res. A

    (2003)
  • Cited by (260)

    View all citing articles on Scopus

    This review is part of the Advanced Drug Delivery Reviews theme issue on “Prediction of Therapeutic and Drug Delivery Outcomes using Animal Models”.

    View full text